

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. (Currently amended) Sachet for a pharmaceutical composition, comprising the layers:
 - i) a paper outer layer;
 - ii) a bonding layer;
 - iii) a barrier layer bonded to the paper by the bonding layer; and
 - iv) a sealing layer as the inner layer.
2. (Currently amended) Sachet according to claim 1, wherein said barrier layer is an aluminum foil, said bonding layer is preferably of polyethylene, and said sealing layer is preferably a low density polyethylene.
3. (Previously presented) Sachet according to claim 1, wherein said paper i) has a weight per unit area of 10-100 g/m².
4. (Original) Sachet according to claim 3, wherein said paper i) has a weight per unit area of 30-70 g/m².
5. (Original) Sachet according to claim 4, wherein said paper i) has a weight per unit area of 40-60 g/m².
6. (Previously presented) Sachet according to claim 1, wherein said bonding layer ii) has a weight per unit area of 6-20 g/m².

7. (Original) Sachet according to claim 6, wherein said bonding layer ii) has a weight per unit area of 9-18 g/m².

8. (Original) Sachet according to claim 7, wherein said bonding layer ii) has a weight per unit area of 12-15 g/m².

9. (Previously presented) Sachet according to claim 1, wherein said sealing layer iv) has a thickness of 15-50 µm.

10. (Currently amended) Sachet according to claim 1, wherein said sealing layer iv) has a weight per unit area of 10-100 g/m², more preferred 15-75 g/m², preferably 20-50 g/m², more preferably 30-40 g/m², most preferred 35 g/m².

11. (Currently amended) Sachet according to claim 1, wherein said barrier layer iii) has a thickness of 6-30 µm, more preferred 7-25 µm, preferably 9-25 µm, more preferred 8-20 µm, preferably 9-15 µm, more preferred 12 µm.

12. (Previously presented) Sachet according to claim 1, containing a pharmaceutical formulation.

13. (Original) Sachet according to claim 12, wherein said pharmaceutical formulation comprises mesalazine or a pharmaceutically acceptable salt thereof.

14. (Previously presented) Sachet according to claim 12, said sachet containing an oral pharmaceutical formulation in the form of a granulate comprising more than 55% by weight of mesalazine or a pharmaceutically acceptable salt thereof.

15. (Currently amended) A method of storing a pharmaceutical composition, comprising storing the pharmaceutical composition in the Use of a sachet according to claim 1 for a pharmaceutical composition.

16. (Currently amended) A method of administering a pharmaceutical composition, comprising:
providing the pharmaceutical composition in the Use of a sachet according to claim 1 for medical purposes;
opening sachet; and
emptying the pharmaceutical composition from the sachet.

17. (New) Sachet according to claim 10, wherein said sealing layer iv) has a weight per unit area of 15-75 g/m².

18. (New) Sachet according to claim 17, wherein said sealing layer iv) has a weight per unit area of 20-50 g/m².

19. (New) Sachet according to claim 18, wherein said sealing layer iv) has a weight per unit area of 30-40 g/m².

20. (New) Sachet according to claim 19, wherein said sealing layer iv) has a weight per unit area of 35 g/m².

21. (New) Sachet according to claim 11, wherein said barrier layer iii) has a thickness of 7-25 µm.

22. (New) Sachet according to claim 21, wherein said barrier layer iii) has a thickness of 9-25 µm.

23. (New) Sachet according to claim 11, wherein said barrier layer iii) has a thickness of 8-20 μm .

24. (New) Sachet according to claim 23, wherein said barrier layer iii) has a thickness of 9-15 μm .

25. (New) Sachet according to claim 24, wherein said barrier layer iii) has a thickness of 12 μm .